Aquestive 制药

Aquestive Therapeutics Inc receives a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 27% discount to our quantitative fair value estimate of $6.36 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet strengthens our valuation estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 7.2 ranks in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

Alternatively, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of -9.9%, a core component of valuation, lies in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.